Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12313464 | 0.85 | ALDH1A1 (0.35) | MEN1KMT2ALMNAALDH1A1NPSR1 | |
| SCHEMBL10044311 | 0.80 | TDP1 (0.44) | MEN1KMT2ALMNATDP1ALDH1A1 | |
| SCHEMBL10044347 | 0.78 | NPC1 (0.35) | MEN1KMT2ALMNATDP1NPC1 | |
| SCHEMBL30040269 | 0.77 | CYP3A4 (0.36) | TDP1ALDH1A1TSHR | |
| SCHEMBL13310715 | 0.77 | TDP1 (0.34) | MEN1KMT2ALMNATDP1NPC1 | |
| SCHEMBL1068540 | 0.76 | CYP3A4 (0.39) | TDP1ALDH1A1TSHR | |
| SCHEMBL10836775 | 0.76 | MTNR1A (0.41) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL5034935 | 0.74 | ALDH1A1 (0.35) | MEN1KMT2ALMNAALDH1A1TSHR | |
| SCHEMBL505809 | 0.73 | TDP1 (0.41) | TDP1ALDH1A1TSHR | |
| SCHEMBL3164447 | 0.72 | TAAR1 (0.46) | MEN1KMT2ALMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263794-B2 | Process for the partial hydrogenation of fatty acid esters | COGNIS IP MANAGEMENT GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20100022664-A1 | Process for the partial hydrogenation of fatty acid esters | COGNIS IP MANAGEMENT GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022664-A1 | Process for the partial hydrogenation of fatty acid esters | ELOVL3, LIPA, FFAR2 | MEN1 4052/4885KMT2A 1355/4885LMNA 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.